Repurposing drugs in oncology (ReDO) - Propranolol as an anti-cancer agent

ecancermedicalscience

Volumn 10, Issue , 2016, Pages

  Pantziarka, Pan ^a,b   Bouche, Gauthier ^a   Sukhatme, Vidula ^c   Meheus, Lydie ^a   Rooman, Ilse ^a,d   Sukhatme, Vikas P ^c,e  

^a Anticancer Fund   (Belgium)

^b George Pantziarka TP53 Trust   (United Kingdom)

^c GlobalCures Inc   (United States)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Beta blockers; Drug repurposing; Propranolol; ReDO project

Indexed keywords

EID: 84996553509     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2016.680     Document Type: Article

References (208)

1. Ali A et al (2015) Propranolol attenuates hemorrhage and accelerates wound healing in severely burned adults Crit Care 19 217 DOI: 10.1186/s13054-015-0913-x PMID: 25936635 PMCID: 4432824
2. Peskind ER et al (2005) Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study Alzheimer Dis Assoc Disord 19(1) 23-8 DOI: 10.1097/01.wad.0000155067.16313.5e PMID: 15764868
3. Greendyke RM et al (1986) Propranolol treatment of assaultive patients with organic brain disease. A double-blind crossover, placebo-controlled study J Nerv and Ment Dis 174(5) 290-4 DOI: 10.1097/00005053-198605000-00005
4. Joint-Formulary-Committee (2015) British National Formulary 69th ed BMJ Group and Pharmaceutical Press
5. Fogari R et al (1990) Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment J Cardiovasc Pharmacol 16(Suppl 5) S76-80 DOI: 10.1097/00005344-199006165-00013 PMID: 11527140
6. McEvoy GK (2004) Propranolol American Society Health-System Pharmacists 1777-84
7. Shand DG (1976) Pharmacokinetics of propranolol: a review Postgrad Med J 52(Suppl 4) 22-5 PMID: 787953
8. Walle T et al (1981) Food-induced increase in propranolol bioavailability-relationship to protein and effects on metabolites Clin Pharmacol Ther 30(6) 790-5 DOI: 10.1038/clpt.1981.239 PMID: 7307427
9. Bowman SL et al (1986) A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. Br J Clinical Pharmacol 21(5) 529-32 DOI: 10.1111/j.1365-2125.1986.tb02837.x
10. Leahey WJ et al (1980) Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol Bri J Cclin Pharmacol 9(1) 33-40 DOI: 10.1111/j.1365-2125.1980.tb04793.x
11. Olesen J, Hougård K and Hertz M (n.d.) Isoproterenol and propranolol: ability to cross the blood-brain barrier and effects on cerebral circulation in man Stroke 9(4) 344-9 DOI: 10.1161/01.STR.9.4.344
12. Filippi L et al (2016) Successful propranolol treatment of a kaposiform hemangioendothelioma apparently resistant to propranolol Pediatr Blood Cancer 63(7) 1290-2
13. Mutschler E, Spahn H and Kirch W (1984) The interaction between H2-receptor antagonists and beta-adrenoceptor blockers Bri J Clin Pharmacol 17 Suppl 1 51S-7S DOI: 10.1111/j.1365-2125.1984.tb02428.x
14. Winniford MD, Huxley RL and Hillis LD (1983) Randomized, double-blind comparison of propranolol alone and a propranolol-verapamil combination in patients with severe angina of effort J Am Coll Cardiol 1(2 Pt 1) 492-8 DOI: 10.1016/S0735-1097(83)80078-3 PMID: 6338082
15. Martin TJ et al (1978) Characterization of beta-adrenergic receptor linked to adenylate cyclase in a human cancer cell line (COLO 16) Clin Sci Mol Med 55(1) 23-9 PMID: 27327
16. Schmitt H and Pochet R (1977) In vivo labelling of beta-adrenergic receptors on rat glioma cells FEBS Lett 76(2) 302-5 DOI: 10.1016/0014-5793(77)80173-7 PMID: 16780
17. Delavier-Klutchko C, Hoebeke J and Strosberg a D (1984) The human carcinoma cell line A431 possesses large numbers of functional beta-adrenergic receptors FEBS Lett 169(2) 151-5 DOI: 10.1016/0014-5793(84)80308-7 PMID: 6143691
18. Ramu A et al (1984) Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells Brit J Cancer 50(4) 501-7 DOI: 10.1038/bjc.1984.207 PMID: 6487516 PMCID: 1976913
19. Tsuruo T et al (1984) Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells Cancer Res 44(10) 4303-7 PMID: 6467192
20. Shiraishi N et al (1986) Lysosomotropic agents reverse multiple drug resistance in human cancer cells Cancer Lett 30(3) 251-9 DOI: 10.1016/0304-3835(86)90049-2
21. Hajighasemi F and Mirshafiey A (2009) In vitro sensitivity of leukemia cells to propranolol. J Clin Med Res 1(3) 144-9 PMID: 22493648 PMCID: 3318877
22. Lamkin DM et al (2012) Chronic stress enhances progression of acute lymphoblastic leukemia via β-adrenergic signaling Brain Behav Immun 26(4) 635-41 DOI: 10.1016/j.bbi.2012.01.013 PMID: 22306453 PMCID: 3322262
23. Hajighasemi F and Hajighasemi S (2009) Effect of propranolol on angiogenic factors in human hematopoietic cell lines in vitro Iran Biomed J 13(4) 223-8 PMID: 19946348
24. Shakhar G and Ben-Eliyahu S (1998) In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats J Immunol 160(7) 3251-8 PMID: 9531281
25. Benish M et al (2008) Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis Ann Surg Oncol 15(7) 2042-52 DOI: 10.1245/s10434-008-9890-5 PMID: 18398660 PMCID: 3872002
26. Goldfarb Y et al (2011) Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses Ann Surg 253(4) 798-810 DOI: 10.1097/SLA.0b013e318211d7b5 PMID: 21475023
27. Sloan EK et al (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer Cancer Res 70(18) 7042-52 DOI: 10.1158/0008-5472.CAN-10-0522 PMID: 20823155 PMCID: 2940980
28. Lang K et al (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs Int J Cancer 112(2) 231-8 DOI: 10.1002/ijc.20410 PMID: 15352035
29. Strell C et al (2012) Norepinephrine promotes the β1-integrin-mediated adhesion of MDA-MB-231 cells to vascular endothelium by the induction of a GROα release Mol Cancer Res 10(2) 197-207 DOI: 10.1158/1541-7786.MCR-11-0130
30. Pasquier E et al (2011) Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment Oncotarget 2(10) 797-809 DOI: 10.18632/oncotarget.343 PMID: 22006582 PMCID: 3248157
31. Campbell JP et al (2012) Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice PLoS biology 10(7) e1001363 DOI: 10.1371/journal.pbio.1001363 PMID: 22815651 PMCID: 3398959
32. Liu D et al (2015) β2-AR signaling controls trastuzumab resistance-dependent pathway. Oncogene 35(1) 1-12
33. Hasegawa H and Saiki I (2002) Psychosocial stress augments tumor development through beta-adrenergic activation in mice Jpn J Cancer Res 93(7) 729-35 DOI: 10.1111/j.1349-7006.2002.tb01313.x PMID: 12149137
34. Dal Monte M et al (2013) Functional involvement of β3-adrenergic receptors in melanoma growth and vascularization J Mol Med (Berl) 91(12) 1407-19 DOI: 10.1007/s00109-013-1073-6
35. Wrobel LJ and Le Gal FA (2014) Inhibition of human melanoma growth by a non-cardioselective β-Blocker J Invest Dermatol 135(2) 1-7
36. Glasner A et al (2010) Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a b-adrenergic antagonist and a cyclooxygenase-2 Inhibitor J Immunol 184(5) 2449-57 DOI: 10.4049/jimmunol. 0903301 PMID: 20124103
37. Lutgendorf SK et al (2002) Vascular endothelial growth factor and social support in patients with ovarian carcinoma Cancer 95(4) 808-15 DOI: 10.1002/cncr.10739
38. Lutgendorf SK et al (2003) Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines Clinical Cancer Res 9(12) 4514-21
39. Sood AK et al (2006) Stress hormone-mediated invasion of ovarian cancer cells Clin Cancer Research 12(2) 369-75 DOI: 10.1158/1078-0432.CCR-05-1698
40. Lee J et al (2009) Surgical stress promotes tumor growth in ovarian carcinoma Clin Cancer Res 15(8) 2695-702 DOI: 10.1158/1078-0432.CCR-08-2966 PMID: 19351748 PMCID: 2746852
41. Léauté-Labrèze C et al (2015) A randomized, controlled trial of oral propranolol in infantile hemangioma New Engl J Med 372(8) 735-46 DOI: 10.1056/NEJMoa1404710 PMID: 25693013
42. Chisholm KM et al (2012) β-Adrenergic receptor expression in vascular tumors. Mod Pathol 25(11) 1446-51 DOI: 10.1038/modpathol. 2012.108 PMID: 22743651
43. Stiles JM et al (2013) Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma PloS One 8(3) e60021 DOI: 10.1371/journal.pone.0060021 PMID: 23555867 PMCID: 3610939
44. Pasquier E et al (2016) Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study EBio Medicine 6 87-95 DOI: 10.1016/j.ebiom.2016.02.026 PMID: 27211551 PMCID: 4856748
45. Pasquier E et al (2013) β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma Br J Cancer 108(12) 2485-94 DOI: 10.1038/bjc.2013.205 PMID: 23695022 PMCID: 3694229
46. Xu T et al (2013) Antiangiogenic effect of propranolol on the growth of the neuroblastoma xenografts in nude mice J Pediatr Surg 48(12) 2460-5 DOI: 10.1016/j.jpedsurg.2013.08.022 PMID: 24314187
47. Wolter JK et al (2014) Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma Oncotarget 5(1) 161-72 PMID: 24389287 PMCID: 3960198
48. Palm D et al (2006) The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers Int J Cancer 118(11) 2744-9 DOI: 10.1002/ijc.21723
49. Brohée L et al (2015) Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment Oncotarget 6(13) 11264-80 DOI: 10.18632/oncotarget.3595 PMID: 25834103 PMCID: 4484455
50. Guo K et al (2009) Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol Oncol Rep 22(4) 825-30 PMID: 19724861
51. Zhang D et al (2009) Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenoceptor antagonist's anticancer effect in pancreatic cancer cell Pancreas 38(1) 94-100 DOI: 10.1097/MPA.0b013e318184f50c
52. Zhang D et al (2010) β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFκB and AP-1 Cancer Biol Ther 10(1) 19-29 DOI: 10.4161/cbt.10.1.11944 PMID: 20424515
53. Kim-Fuchs C et al (2014) Chronic stress accelerates pancreatic cancer growth and invasion: a critical role for beta-adrenergic signaling in the pancreatic microenvironment Brain Behav Immun 40 40-7 DOI: 10.1016/j.bbi.2014.02.019 PMID: 24650449 PMCID: 4102665
54. Partecke LI et al (2016) Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade Pancreatology 16(3) 423-33 DOI: 10.1016/j.pan.2016.03.005 PMID: 27083074
55. Masur K et al (2001) Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers Cancer Res 61(7) 2866-9 PMID: 11306460
56. Coelho M et al (2015) Antiproliferative effects of β-blockers on human colorectal cancer cells Oncol Rep 33(5) 2513-20 PMID: 25812650
57. Chin C-C et al (2016) Selective β2-AR blockage suppresses colorectal cancer growth through regulation of EGFR-Akt/ERK1/2 signaling, G1-phase arrest and apoptosis J Cell Physiol 231(2) 459-72 DOI: 10.1002/jcp.25092
58. Lin Q et al (2013) Effect of chronic restraint stress on human colorectal carcinoma growth in mice PloS One 8(4) e61435 DOI: 10.1371/journal.pone.0061435 PMCID: 3621827
59. Yang EV et al (2006) Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells Cancer Res 66(21) 10357-64 DOI: 10.1158/0008-5472. CAN-06-2496 PMID: 17079456
60. Annabi B et al (2009) Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase- 9 secretion Pharmacological Res 60(5) 438-45 DOI: 10.1016/j.phrs.2009.05.005
61. Bernabé DG et al (2011) Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinoma cells Brain Behav Immun 25(3) 574-83 DOI: 10.1016/j.bbi.2010.12.012
62. Wolter NE et al (2012) Propranolol as a novel adjunctive treatment for head and neck squamous cell carcinoma J Otolaryngol Head Neck Surg 41(5) 334-44 PMID: 23092836
63. Grzanna R et al (1985) In vivo administration of propranolol delays development of a murine plasmacytoma tumor J Auton Nerv Syst 14(4) 397-401 DOI: 10.1016/0165-1838(85)90085-2 PMID: 4086728
64. Bomber P, McCready R and Hammersley P (1986) Propranolol hydrochloride enhancement of tumor perfusion and uptake of gallium-67 in a mouse sarcoma J Nucl Med 27(2) 243-5 PMID: 3712042
65. Burton M and Gray BN (1987) Redistribution of blood flow in experimental hepatic tumours with noradrenaline and propranolol Br J Cancer 56(5) 585-8 DOI: 10.1038/bjc.1987.245 PMID: 3426921 PMCID: 2001891
66. Liao X et al (2010) The β-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor κB signaling Oncol Rep 24(6) 1669-76 PMID: 21042766
67. Liao X et al (2010) Effects of propranolol in combination with radiation on apoptosis and survival of gastric cancer cells in vitro Radiat Oncol (London, England) 5 98 DOI: 10.1186/1748-717X-5-98
68. Al-Wadei HA, Al-Wadei MH and Schuller HM (2012) Cooperative regulation of non-small cell lung carcinoma by nicotinic and beta-adrenergic receptors: a novel target for intervention PLoS. One 7(1) e29915 DOI: 10.1371/journal.pone.0029915
69. Al-Wadei MH, Al-Wadei HAN and Schuller HM (2012) Pancreatic cancer cells and normal pancreatic duct epithelial cells express an autocrine catecholamine loop that is activated by nicotinic acetylcholine receptors α3, α5, and α7 Mol Cancer Res 10(2) 239-49 DOI: 10.1158/1541-7786.MCR-11-0332 PMCID: 3340883
70. Kozanoglu I et al (2013) New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma J Cancer Res Clin Oncol 139(2) 327-35 DOI: 10.1007/s00432-012-1331-y
71. Abdin AA, Soliman NA and Saied EM (2014) Effect of propranolol on IL-10, visfatin, Hsp70, iNOS, TLR2, and survivin in amelioration of tumor progression and survival in Solid Ehrlich Carcinoma-bearing mice Pharmacol Rep 66(6) 1114-21 DOI: 10.1016/j. pharep.2014.07.010 PMID: 25443743
72. Wei W-J et al (2016) Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib Oncol Rep 36(3) 1576-84 PMID: 27432558
73. Albiñana V et al (2015) Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients Orphanet J Rare Dis 10(1) 118 DOI: 10.1186/s13023-015-0343-5 PMID: 26394686 PMCID: 4579575
74. Perron L et al (2004) Antihypertensive drug use and the risk of prostate cancer (Canada) Cancer Causes Control 15(6) 535-41 DOI: 10.1023/B:CACO.0000036152.58271.5e PMID: 15280632
75. Nkontchou G et al (2012) Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis Cancer Prev Res (Philadelphia, Pa.) 5(8) 1007-14 DOI: 10.1158/1940-6207.CAPR-11-0450
76. Chang P-Y et al (2015) Propranolol reduces cancer risk: a population-based cohort study Medicine(Baltimore) 94(27) p. e1097
77. Zhong S et al (2015) β-Blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies Eur J Cancer Prev 25(5) 440-8 DOI: 10.1097/CEJ.0000000000000192 PMID: 26340056
78. Weberpals J et al (2016) Beta blockers and cancer prognosis - The role of immortal time bias: A systematic review and metaanalysis Cancer Treat Rev 47 1-11 DOI: 10.1016/j.ctrv.2016.04.004 PMID: 27179912
79. Barron TI et al (2011) Beta blockers and breast cancer mortality: a population-based study J Clin Oncol 29(19) 2635-44 DOI: 10.1200/JCO.2010.33.5422 PMID: 21632503
80. Childers WK, Hollenbeak CS and Cheriyath P (2015) β-Blockers Reduce Breast Cancer Recurrence and Breast Cancer Death: A Meta-Analysis Clin Breast Cancer 15(6) 426-31 DOI: 10.1016/j.clbc.2015.07.001 PMID: 26516037
81. Banavali S, Pasquier E and Andre N (2015) Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma Ecancermedicalscience 9 499 DOI: 10.3332/ecancer. 2015.499 PMID: 25624880 PMCID: 4303616
82. Chow W et al (2015) Growth attenuation of cutaneous angiosarcoma with propranolol-mediated β-blockade JAMA Dermatol 151(11) 1226-9 DOI: 10.1001/jamadermatol.2015.2554 PMID: 26375166
83. Bhattacharyya GS et al (2014) Continuous metronomic temozolamide with propranolol and etodolac in recurrent globlastoma: A pilot study in ASCO Annual Meeting Proceedings e13005
84. Shahid T et al (2015) Continuous low dose temozolamide with or without VT-122 in glioblastoma in ASCO Annual Meeting Proceedings e13010
85. Bhattacharyya GS et al (2015) Effect of coadministered beta blocker and COX-2 inhibitor to patients with pancreatic cancer prior to receiving albumin-bound (Nab) paclitaxel in ASCO Annual Meeting Proceedings
86. de la Torre AN et al (2015) Effect of coadministration of propranolol and etodolac (VT-122) plus sorafenib for patients with advanced hepatocellular carcinoma (HCC) J Clin Oncol 33(suppl 3; abstr 390)
87. Aoyagi T et al (2015) Cancer cachexia, mechanism and treatment World J Gastrointest Oncol 7(4) 17-29 PMID: 25897346 PMCID: 4398892
88. Hyltander A, Körner U and Lundholm KG (1993) Evaluation of mechanisms behind elevated energy expenditure in cancer patients with solid tumours Euro J Clin Invest 23(1) 46-52 DOI: 10.1111/j.1365-2362.1993.tb00716.x
89. Hyltander A et al (2000) Beta-adrenoceptor activity and resting energy metabolism in weight losing cancer patients Eur J Cancer 36(3) 330-4 DOI: 10.1016/S0959-8049(99)00273-7
90. Lindgren ME et al (2013) Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients Psychooncology 22(8) 1889-94 DOI: 10.1002/pon.3233 PMCID: 3612565
91. Hoffmann C et al (2004) Comparative pharmacology of human beta-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells Naunyn-Schmiedebergs Arch Pharmacol 369(2) 151-9 DOI: 10.1007/s00210-003-0860-y PMID: 14730417
92. Qinye F et al (2014) Carvedilol suppresses migration and invasion of malignant breast cells by inactivating Src involving cAMP/PKA and PKCδ signaling pathway J Cancer Res Ther 10(4) 998-1003 DOI: 10.4103/0973-1482.137664
93. Lin C-S et al (2015) Carvedilol use is associated with reduced cancer risk: A nationwide population-based cohort study Int J Cardiol 184 9-13 DOI: 10.1016/j.ijcard.2015.02.015 PMID: 25705003
94. Cole SW et al (2015) Sympathetic nervous system regulation of the tumour microenvironment Nat Rev Cancer 15(9) 563-72 DOI: 10.1038/nrc3978 PMID: 26299593 PMCID: 4828959
95. Selye H, Veilleux R and Cantin M (1961) Excessive stimulation of salivary gland growth by isoproterenol Science 133(3445) 44-5 DOI: 10.1126/science.133.3445.44 PMID: 13749973
96. BARKA T (1965) Induced cell proliferation: the effect of isoproterenol Exp Cell Res 37(1865) 662-79 DOI: 10.1016/0014-4827(65)90214-4 PMID: 14315088
97. Iwata H, Kariya K and Fujimoto S (1969) Effect of compounds affecting the adrenergic mechanism on cell growth and division of Tetrahymena pyriformis W Jpn J Pharmacol 19(2) 275-81 DOI: 10.1254/jjp.19.275 PMID: 4391852
98. Bijman JT et al (1987) Modulation of placental alkaline phosphatase activity and cytokeratins in human HN-1 cells by butyrate, retinoic acid, catecholamines and histamine Br J Cancer 56(2) 127-32 DOI: 10.1038/bjc.1987.169 PMID: 2444242 PMCID: 2002146
99. Schuller HM and Cole B (1989) Regulation of cell proliferation by beta-adrenergic receptors in a human lung adenocarcinoma cell line Carcinogenesis 10(9) 1753-5 DOI: 10.1093/carcin/10.9.1753 PMID: 2569945
100. Lin X et al (2012) Beta-adrenoceptor action on pancreatic cancer cell proliferation and tumor growth in mice Hepatogastroenterology 59(114) 584-8 PMID: 22353526
101. Işeri OD et al (2014) beta-Adrenoreceptor antagonists reduce cancer cell proliferation, invasion, and migration Pharm Biol 52(11) 1374-81 DOI: 10.3109/13880209.2014.892513 PMID: 25026350
102. Pérez Piñero C et al (2012) Involvement of α2- and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation Br J Pharmacol 166(2) 721-36 DOI: 10.1111/j.1476-5381.2011.01791.x PMCID: 3417500
103. Valles SL et al (2013) Stress hormones promote growth of B16-F10 melanoma metastases: an interleukin 6- and glutathionedependent mechanism J Transl Med 11 72 DOI: 10.1186/1479-5876-11-72 PMID: 23517603 PMCID: 3608962
104. Shay G, Lynch CC and Fingleton B (2015) Moving targets: Emerging roles for MMPs in cancer progression and metastasis Matrix Biol 44-6 200-6 DOI: 10.1016/j.matbio.2015.01.019
105. Yadav L et al (2014) Matrix metalloproteinases and cancer - roles in threat and therapy. Asian Pac J Cancer Prev 15(3) 1085-91 DOI: 10.7314/APJCP.2014.15.3.1085 PMID: 24606423
106. Moretti S et al (2013) β-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines Lab Invest 93(3) 279-90 DOI: 10.1038/labinvest.2012.175 PMID: 23318885
107. Barbieri A et al (2015) The stress hormone norepinephrine increases migration of prostate cancer cells in vitro and in vivo Int J Oncol 47(2) 527-34 PMID: 26058426
108. Annabi B et al (2010) Pharmacological targeting of β-adrenergic receptor functions abrogates NF-κB signaling and MMP-9 secretion in medulloblastoma cells Onco Targets Ther 3 219-26 DOI: 10.2147/OTT.S14503 PMID: 21124749 PMCID: 2994204
109. Wu S et al (2015) Clinical efficacy of propranolol in the treatment of hemangioma and changes in serum VEGF, bFGF and MMP-9 Exp Ther Medicine 10(3) 1079-83
110. Thaivalappil S et al (2013) Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas JAMA Otolaryngol Head Neck Surg 139(10) 1026-31 DOI: 10.1001/jamaoto.2013.4773 PMID: 24135743
111. Pon CK et al (2016) The β2-adrenoceptor activates a positive cAMP-calcium feedforward loop to drive breast cancer cell invasion FASEB J 30(3) 1144-54 DOI: 10.1096/fj.15-277798
112. Smith BN and Bhowmick NA (2016) Role of EMT in metastasis and therapy resistance J Clin Med 5(2) 17 DOI: 10.3390/jcm5020017 PMCID: 4773773
113. Shan T et al (2014) Novel regulatory program for norepinephrine-induced epithelial-mesenchymal transition in gastric adenocarcinoma cell lines Cancer Sci 105(7)847-56 DOI: 10.1111/cas.12438 PMID: 24815301 PMCID: 4317918
114. Zhang J et al (2016) Norepinephrine induced epithelial-mesenchymal transition in HT-29 and A549 cells in vitro J Cancer Res Clin Oncol 142(2) 423-35 DOI: 10.1007/s00432-015-2044-9
115. Jacob A and Prekeris R (2015) The regulation of MMP targeting to invadopodia during cancer metastasis Front Cell Dev Biol 3 4 DOI: 10.3389/fcell.2015.00004 PMID: 25699257 PMCID: 4313772
116. Creed SJ et al (2015) β2-adrenoceptor signaling regulates invadopodia formation to enhance tumor cell invasion Breast Cancer Res 17(1) 145 DOI: 10.1186/s13058-015-0655-3 PMID: 26607426 PMCID: 4660629
117. Linden J (2013) Adenosine promotes tumor metastasis Sci Signal 6(277) pe20 DOI: 10.1126/scisignal.2004290 PMID: 23716715
118. Ntantie E et al (2013) An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering Sci Signal 6(277) ra39 DOI: 10.1126/scisignal.2003374 PMID: 23716716 PMCID: 4278376
119. Wilson JM et al (2015) β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells Cancer Biol Ther 16(9) 1364-74 DOI: 10.1080/15384047.2015.1070988 PMID: 26209110 PMCID: 4622671
120. Psaila B and Lyden D (2009) The metastatic niche: adapting the foreign soil Nat Rev Cancer 9(4) 285-93 DOI: 10.1038/nrc2621 PMID: 19308068 PMCID: 3682494
121. Barcellos-Hoff MH, Lyden D and Wang TC (2013) The evolution of the cancer niche during multistage carcinogenesis Nat Rev Cancer 13(7) 511-8 DOI: 10.1038/nrc3536 PMID: 23760023
122. Karaman S and Detmar M (2014) Mechanisms of lymphatic metastasis J Clin Invest 124(3) 922-8 DOI: 10.1172/JCI71606 PMID: 24590277 PMCID: 3938272
123. Le CP et al (2016) Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination Nat Commun 7 10634 DOI: 10.1038/ncomms10634 PMID: 26925549 PMCID: 4773495
124. Ozeki M et al (2013) Propranolol as an alternative treatment option for pediatric lymphatic malformation Tohoku J Exp Med 229(1) 61-6 DOI: 10.1620/tjem.229.61
125. Asano A et al (1997) Adrenergic activation of vascular endothelial growth factor mRNA expression in rat brown adipose tissue: implication in cold-induced angiogenesis Biochem J 328(1) 179-83 DOI: 10.1042/bj3280179
126. Tonello C et al (1999) Role of sympathetic activity in controlling the expression of vascular endothelial growth factor in brown fat cells of lean and genetically obese rats FEBS Lett 442(2-3) 167-72 DOI: 10.1016/S0014-5793(98)01627-5 PMID: 9928995
127. Thaker PH et al (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma Nat Med 12(8) 939-44 DOI: 10.1038/nm1447 PMID: 16862152
128. Yang EV et al (2009) Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression Brain Behav Immun 23(2) 267-75 DOI: 10.1016/j.bbi.2008.10.005 PMCID: 2652747
129. Lamy S et al (2010) Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells Vascul Pharmacol 53(5-6) 200-8 DOI: 10.1016/j.vph.2010.08.002 PMID: 20732454
130. Kum JJ and Khan ZA (2015) Mechanisms of propranolol action in infantile hemangioma Dermato-endocrinology 6(1) e979699 DOI: 10.4161/19381980.2014.979699 PMCID: 4580045
131. Léauté-Labrèze C et al (2008) Propranolol for severe hemangiomas of infancy New Engl J Med 358(24) 2649-51 DOI: 10.1056/NEJMc0708819 PMID: 18550886
132. Park SY et al (2011) Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1α proteindependent mechanism Int J Cancer 128(10) 2306-16 DOI: 10.1002/ijc.25589
133. Shan T et al (2013) β2-AR-HIF-1α: a novel regulatory axis for stress-induced pancreatic tumor growth and angiogenesis Curr Mol Med 13(6) 1023-34 DOI: 10.2174/15665240113139990055 PMID: 23745588 PMCID: 4104615
134. Muraki C et al (2012) Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells Int J Cancer 130(1) 59-70 DOI: 10.1002/ijc.25976
135. Iñiguez MA et al (2003) Cyclooxygenase-2: a therapeutic target in angiogenesis Trends Mol Med 9(2) 73-8 DOI: 10.1016/S1471-4914(02)00011-4 PMID: 12615041
136. Ciccarelli M et al (2011) Impaired neoangiogenesis in β2-adrenoceptor gene-deficient mice: restoration by intravascular human β2-adrenoceptor gene transfer and role of NFκB and CREB transcription factors Bri J Pharmacol 162(3) 712-21 DOI: 10.1111/j.1476-5381.2010.01078.x
137. Zamora JM, Pearce HL and Beck WT (1988) Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells Mol Pharmacol 33(4) 454-62 PMID: 3162758
138. Bando T et al (1997) Stimulation of beta-adrenoceptor enhances sensitivity to cisplatin in non-small cell lung cancer cell lines Int J Ooncol 10(6) 1197-201
139. Akutsu Y et al (2011) COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma Ann Surg Oncol 18(10) 2946-51 DOI: 10.1245/s10434-011-1645-z PMID: 21437756
140. Xia S et al (2010) Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells Cancer Biother Radiopharm 25(3) 317-23 DOI: 10.1089/cbr.2009.0707 PMID: 20578837
141. Yang HJ et al (2013) Investigation of radiation-induced transcriptome profile of radioresistant non-small cell lung cancer A549 cells using RNA-seq PloS One 8(3) e59319 DOI: 10.1371/journal.pone.0059319 PMID: 23533613 PMCID: 3606344
142. Liu J et al (2015) The effect of chronic stress on anti-angiogenesis of sunitinib in colorectal cancer models Psychoneuroendocrinology 52 130-42 DOI: 10.1016/j.psyneuen.2014.11.008
143. Green McDonald P, O'Connell M and Lutgendorf SK (2013) Psychoneuroimmunology and cancer: A decade of discovery, paradigm shifts, and methodological innovations Brain Behav Immun 30(Suppl) S1-9 DOI: 10.1016/j.bbi.2013.01.003 PMID: 23333846 PMCID: 3907949
144. Segerstrom SC and Miller GE (2004) Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry Psychol Bull 130(4) 601-30 DOI: 10.1037/0033-2909.130.4.601 PMID: 15250815 PMCID: 1361287
145. Glaser R and Kiecolt-Glaser JK (2005) Stress-induced immune dysfunction: implications for health Nat Rev Immunol 5(3) 243-51 DOI: 10.1038/nri1571 PMID: 15738954
146. Teshima H et al (1990) Prevention of immunosuppression in stressed mice by neurotropin(NSP) Life Sci 47(10) 869-76 DOI: 10.1016/0024-3205(90)90600-V PMID: 2215070
147. Kalinichenko VV et al (1999) Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a beta-adrenergic receptor mechanism and decreased TNF-alpha gene expression J Immunol 163(5) 2492-9 PMID: 10452985
148. Wu W et al (2000) Social isolation stress enhanced liver metastasis of murine colon 26-L5 carcinoma cells by suppressing immune responses in mice Life Sci 66(19) 1827-38 DOI: 10.1016/S0024-3205(00)00506-3 PMID: 10809180
149. Kanemi O et al (2005) Acute stress reduces intraparenchymal lung natural killer cells via beta-adrenergic stimulation Clin Exp Immunol 139(1) 25-34 DOI: 10.1111/j.1365-2249.2005.02672.x
150. Tarr AJ et al (2012) β-Adrenergic receptor mediated increases in activation and function of natural killer cells following repeated social disruption Brain Behav Immun 26(8) 1226-38 DOI: 10.1016/j.bbi.2012.07.002 PMID: 22796551 PMCID: 3468689
151. Ben-Eliyahu S (2012) Can we really know if a stressor increases or decreases natural killer cell activity? Brain Bbehav Immun 26(8) 1224-5 DOI: 10.1016/j.bbi.2012.08.004
152. Sonnenfeld G et al (1992) Stress-induced alterations in interferon production and class II histocompatibility antigen expression Brain Behav Immun 6(2) 170-8 DOI: 10.1016/0889-1591(92)90016-H PMID: 1504370
153. Khalili A et al (2013) Long acting propranolol and HSP-70 rich tumor lysate reduce tumor growth and enhance immune response against fibrosarcoma in Balb/c mice Iran J Immunol 10(2) 70-82 PMID: 23811546
154. Huang H-W et al (2013) Lymphocyte-derived catecholamines induce a shift of Th1/Th2 balance toward Th2 polarization Neuroimmunomodulation 20(1) 1-8 DOI: 10.1159/000343099
155. 2-adrenoceptors Neuroimmunomodulation 22(3) 138-51 DOI: 10.1159/000360579
156. Panina-Bordignon P et al (1997) Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12 J Clin Invest 100(6) 1513-9 DOI: 10.1172/JCI119674 PMID: 9294119 PMCID: 508332
157. Khaled YS, Ammori BJ and Elkord E (2013) Myeloid-derived suppressor cells in cancer: recent progress and prospects Immunol Cell Biol 91(8) 493-502 DOI: 10.1038/icb.2013.29 PMID: 23797066
158. Motallebnezhad M et al (2015) The immunobiology of myeloid-derived suppressor cells in cancer Tumour Biol 37(2) 1387-406 DOI: 10.1007/s13277-015-4477-9 PMID: 26611648
159. Jin J et al (2013) Chronic psychological stress induces the accumulation of myeloid-derived suppressor cells in mice PloS One 8(9) e74497 DOI: 10.1371/journal.pone.0074497 PMID: 24058577 PMCID: 3776856
160. Mao Y et al (2014) Inhibition of tumor-derived prostaglandin-E2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity Clin Cancer Res 20(15) 4096-106 DOI: 10.1158/1078-0432.CCR-14-0635 PMID: 24907113
161. Zhou L et al (2016) Propranolol Attenuates Surgical Stress-Induced Elevation of the Regulatory T Cell Response in Patients Undergoing Radical Mastectomy J Immunol 196(8) 3460-9 DOI: 10.4049/jimmunol.1501677 PMID: 26969754
162. Normanno N et al (2006) Epidermal growth factor receptor (EGFR) signaling in cancer Gene 366(1) 2-16 DOI: 10.1016/j. gene.2005.10.018
163. Rush JS et al (2012) Endosomal accumulation of the activated epidermal growth factor receptor (EGFR) induces apoptosis J Biol Chem 287(1) 712-22 DOI: 10.1074/jbc.M111.294470 PMCID: 3249126
164. Mosesson Y, Mills GB and Yarden Y (2008) Derailed endocytosis: an emerging feature of cancer Nat Rev Cancer 8(11) 835-50 DOI: 10.1038/nrc2521 PMID: 18948996
165. Shaughnessy R et al (2014) Epidermal growth factor receptor endocytic traffic perturbation by phosphatidate phosphohydrolase inhibition: New strategy against cancer FEBS J 281(9) 2172-89 DOI: 10.1111/febs.12770 PMID: 24597955
166. Norambuena A et al (2010) Phosphatidic acid induces ligand-independent epidermal growth factor receptor endocytic traffic through PDE4 activation Mol Biol Cell 21(16) 2916-29 DOI: 10.1091/mbc.E10-02-0167 PMID: 20554760 PMCID: 2921116
167. Lavie Y, Piterman O and Liscovitch M (1990) Inhibition of phosphatidic acid phosphohydrolase activity by sphingosine. Dual action of sphingosine in diacylglycerol signal termination FEBS Lett 277(1-2) 7-10 DOI: 10.1016/0014-5793(90)80796-L PMID: 2269371
168. Kang F et al (2014) Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2 J Nucl Med 55(3) 439-45 DOI: 10.2967/jnumed.113.121327 PMID: 24504055 PMCID: 4564063
169. Nakanishi M and Rosenberg DW (2013) Multifaceted roles of PGE2 in inflammation and cancer Semin Immunopath 35(2) 123-137 DOI: 10.1007/s00281-012-0342-8
170. Nagaraja AS et al (2015) Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis Oncogene 35(18) 2390-7 DOI: 10.1038/onc.2015.302 PMID: 26257064 PMCID: 4749473
171. Gay LJ and Felding-Habermann B (2011) Contribution of platelets to tumour metastasis Nat Rev Cancer 11(2) 123-34 DOI: 10.1038/nrc3004 PMID: 21258396
172. Su BB et al (2014) Aspirin may modify tumor microenvironment via antiplatelet effect Med Hypotheses 1 7-9
173. Mikami J et al (2015) Antitumor effect of antiplatelet agents in gastric cancer cells: an in vivo and in vitro study Gastric Cancer 19(3) 817-26 DOI: 10.1007/s10120-015-0556-2 PMID: 26486505
174. Mousa S a and Petersen LJ (2009) Anti-cancer properties of low-molecular-weight heparin: preclinical evidence Thromb Haemost 102(2) 258-67 PMID: 19652876
175. Pfankuchen DB et al (2015) Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells Biochem Pharmacol 97(2) 147-57 DOI: 10.1016/j.bcp.2015.07.013 PMID: 26239805
176. Spano D et al (2013) Dipyridamole prevents triple-negative breast-cancer progression Clin Exp Metastasis 30(1) 47-68 DOI: 10.1007/s10585-012-9506-0
177. Bonten TN et al (2014) Effect of β-blockers on platelet aggregation: a systematic review and meta-analysis Br J Clin Pharmacol 78(5) 940-9 DOI: 10.1111/bcp.12404 PMID: 24730697 PMCID: 4243868
178. Punda A et al (2005) Effects of atenolol and propranolol on platelet aggregation in moderate essential hypertension: randomized crossover trial Croat Med J 46(2) 219-24 PMID: 15849842
179. Aschbacher K et al (2013) Good stress, bad stress and oxidative stress: Insights from anticipatory cortisol reactivity Psychoneuroendocrinology 38(9) 1698-708 DOI: 10.1016/j.psyneuen.2013.02.004 PMID: 23490070 PMCID: 4028159
180. Cao L et al (2010) Environmental and genetic activation of a brain-adipocyte BDNF/leptin axis causes cancer remission and inhibition Cell 142(1) 52-64 DOI: 10.1016/j.cell.2010.05.029 PMID: 20603014 PMCID: 3784009
181. Buehler D et al (2014) Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience Am J Clin Oncol 37(5) 473-9 DOI: 10.1097/COC.0b013e31827e4e7b
182. Penel N et al (2011) Angiosarcoma: state of the art and perspectives Crit Rev Oncol Hematol 80(2) 257-63 DOI: 10.1016/j.critrevonc. 2010.10.007
183. Hermans DJJ et al (2011) Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment J Pediatr Hematol Oncol 33(4) e171-3 DOI: 10.1097/MPH.0b013e3182152e4e PMID: 21516018
184. Ozeki M, Fukao T and Kondo N (2011) Propranolol for intractable diffuse lymphangiomatosis N Engl J Med 364(14) 1380-2 DOI: 10.1056/NEJMc1013217 PMID: 21470038
185. Coghlin C and Murray GI (2010) Current and emerging concepts in tumour metastasis J Pathol 222(1) 1-15 DOI: 10.1002/path.2727 PMID: 20681009
186. Shaked Y (2016) Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects Nat Rev Clin Oncol 13(10) 611-26 DOI: 10.1038/nrclinonc.2016.57 PMID: 27118493
187. Horowitz M et al (2015) Exploiting the critical perioperative period to improve long-term cancer outcomes Nat Rev Clin Oncol 12(4) 213-26 DOI: 10.1038/nrclinonc.2014.224 PMID: 25601442
188. Antonio N et al (2015) The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer EMBO J 34(17) 2219-36 DOI: 10.15252/embj.201490147 PMID: 26136213 PMCID: 4585460
189. Neeman E and Ben-Eliyahu S (2013) Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement Brain Behav Immun 30 Suppl S32-40 DOI: 10.1016/j.bbi.2012.03.006
190. Gottschalk A et al (2010) The role of the perioperative period in recurrence after cancer surgery Anesth Anal 110(6) 1636-43 DOI: 10.1213/ANE.0b013e3181de0ab6
191. Opitz I et al (2013) Perioperative diclofenac application during video-assisted thoracic surgery pleurodesis modulates early inflammatory and fibrinolytic processes in an experimental model Eur Surg Res 50(1) 14-23 DOI: 10.1159/000341670 PMID: 23429206
192. Shakhar G and Ben-Eliyahu S (2003) Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 10(8) 972-92 DOI: 10.1245/ASO.2003.02.007 PMID: 14527919
193. Horowitz M et al (2015) Exploiting the critical perioperative period to improve long-term cancer outcomes Nat Rev Clin Oncol 12(4) 213-26 DOI: 10.1038/nrclinonc.2014.224 PMID: 25601442
194. Ash S and Buggy DJ (2013) Does regional anaesthesia and analgesia or opioid analgesia influence recurrence after primary cancer surgery? An update of available evidence Best Prac Res Clin Anaesthesiol 27(4) 441-56 DOI: 10.1016/j.bpa.2013.10.005
195. Heaney Á and Buggy DJ (2012) Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Bri J Anaesth 109(SUPPL1) i17-i28 DOI: 10.1093/bja/aes421
196. Forget P et al (2013) Perioperative ketorolac in high risk breast cancer patients. Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial Med Hypotheses 81(4) 707-12 DOI: 10.1016/j.mehy.2013.07.033 PMID: 23937996
197. Retsky M et al (2012) NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup Breast Cancer Res Treat 134(2) 881-8 DOI: 10.1007/s10549-012-2094-5 PMID: 22622810
198. Guo Y et al (2015) A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients Clin Cancer Res 21(22) 5064-72 DOI: 10.1158/1078-0432.CCR-15-0461 PMID: 26071482 PMCID: 4644688
199. Forget P et al (2014) Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery Br J Anaesth 113(Suppl 1) i82-7 DOI: 10.1093/bja/aet464 PMID: 24464611
200. Forget P et al (2013) Neutrophil: lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery Ann Surg Oncol 20(Suppl 3) S650-60 DOI: 10.1245/s10434-013-3136-x PMID: 23884751
201. Pantziarka P et al (2014) Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent Ecancermedicalscience 8 485 DOI: 10.3332/ecancer.2014.485 PMID: 25525463 PMCID: 4268104
202. Deva S and Jameson M (2012) Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer Cochrane Database Syst Rev 8(8) CD007814 PMID: 22895966
203. Eng JW-L et al (2014) A nervous tumor microenvironment: the impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic response Cancer Immun Immunother 63(11) 1115-28 DOI: 10.1007/s00262-014-1617-9
204. Thaker PH, Sood AK and Ramondetta LM (2013) Importance of adrenergic pathways in women's cancers Cancer Biomarkers 13(3) 145-54
205. Pantziarka P et al (2016) Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent Ecancermedicalscience 10 610 DOI: 10.3332/ecancer.2016.610 PMID: 26823679 PMCID: 4720497
206. Zhang M-F et al (2015) Effectiveness of mindfulness-based therapy for reducing anxiety and depression in patients with cancer: a meta-analysis Medicine (Baltimore) 94(45) e0897-0 DOI: 10.1097/MD.0000000000000897
207. Stagl JM et al (2015) A randomized controlled trial of cognitive-behavioral stress management in breast cancer: survival and recurrence at 11-year follow-up Breast Cancer Research Treat 154(2) 319-28 DOI: 10.1007/s10549-015-3626-6
208. Fancourt D et al (2016) Singing modulates mood, stress, cortisol, cytokine and neuropeptide activity in cancer patients and carers Ecancermedicalscience 10 631 DOI: 10.3332/ecancer.2016.631 PMID: 27170831 PMCID: 4854222